AD-PluReceptor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AD-PluReceptor, covering 2026-04-15 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders [Phase 1, Phase 2]